"Study","Study.year","Analysis.name","Analysis.number","Subgroup.number","Experimental.cases","Experimental.N","Control.cases","Control.N","Experimental.mean","Experimental.SD","Control.mean","Control.SD","GIV.Mean","GIV.SE","Mean","CI.start","CI.end","Variance","Weight","analysis_key","dataset_name","exp_cases_gt_n","ctrl_cases_gt_n","exp_cases_lt0","ctrl_cases_lt0","exp_n_le0","ctrl_n_le0","exp_cases_nonint","ctrl_cases_nonint","exp_n_nonint","ctrl_n_nonint","double_zero","all_events","sparse_events","exp_sd_le0","ctrl_sd_le0","variance_negative","giv_se_negative","ci_inverted","ci_mismatch"
"Genovese 2007",2007,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,13,51,1,51,0,0,0,0,0,0,13,1.765395,95.729258,0,2.487461,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,161,429,56,423,0,0,0,0,0,0,2.83479,2.157963,3.723898,0,13.211729,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,64,140,28,281,0,0,0,0,0,0,4.587755,3.090354,6.810707,0,12.120547,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,54,153,6,162,0,0,0,0,0,0,9.529412,4.222403,21.506635,0,8.015881,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,30,101,5,106,0,0,0,0,0,0,6.29703,2.54314,15.591978,0,7.243327,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,35,106,10,105,0,0,0,0,0,0,3.466981,1.811908,6.633869,0,9.559505,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,27,72,3,24,0,0,0,0,0,0,3,0.998909,9.009828,0,5.869756,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,2,94,273,15,136,0,0,0,0,0,0,3.121856,1.884764,5.170931,0,11.022379,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,3,15,30,1,30,0,0,0,0,0,0,15,2.112952,106.486071,0,2.564543,"1::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,3,39,101,5,104,0,0,0,0,0,0,8.031683,3.298777,19.555106,0,7.37817,"1::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,4,87,292,1,113,0,0,0,0,0,0,33.667808,4.746192,238.827521,0,2.566188,"1::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,4,105,241,15,239,0,0,0,0,0,0,6.941909,4.166258,11.566756,0,10.96167,"1::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,5,24,52,0,52,0,0,0,0,0,0,49,3.05836,785.061256,0,1.405736,"1::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,5,36,100,3,100,0,0,0,0,0,0,12,3.819789,37.698417,0,5.593107,"1::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,190,429,80,423,0,0,0,0,0,0,2.341783,1.87172,2.929897,0,15.666958,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,59,153,10,162,0,0,0,0,0,0,6.247059,3.317831,11.762425,0,12.550905,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,39,101,16,106,0,0,0,0,0,0,2.558168,1.529858,4.277668,0,13.602373,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,2,115,273,17,136,0,0,0,0,0,0,3.369963,2.114906,5.369814,0,14.009881,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,3,41,101,7,104,0,0,0,0,0,0,6.031117,2.839434,12.810434,0,11.463319,"2::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,4,102,292,4,113,0,0,0,0,0,0,9.868151,3.721714,26.165474,0,9.561959,"2::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,4,129,241,15,239,0,0,0,0,0,0,8.528631,5.153007,14.115554,0,13.690444,"2::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,5,41,100,4,100,0,0,0,0,0,0,10.25,3.81419,27.545164,0,9.454161,"2::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,1,107,429,27,423,0,0,0,0,0,0,3.907537,2.618836,5.830393,0,27.452264,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,1,63,140,37,281,0,0,0,0,0,0,3.417568,2.404242,4.857985,0,30.175527,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,1,27,106,7,105,0,0,0,0,0,0,3.820755,1.740499,8.387348,0,12.863582,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,1,29,72,4,24,0,0,0,0,0,0,2.416667,0.946124,6.172847,0,9.872324,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,2,67,292,1,113,0,0,0,0,0,0,25.928082,3.64285,184.543828,0,2.707541,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",3,2,65,241,10,239,0,0,0,0,0,0,6.446058,3.39463,12.240412,0,16.928761,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,1,143,429,52,423,0,0,0,0,0,0,2.711538,2.033864,3.615012,0,25.835202,"4::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,1,32,101,16,106,0,0,0,0,0,0,2.09901,1.229743,3.582736,0,20.591654,"4::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,2,92,273,8,136,0,0,0,0,0,0,5.728938,2.866191,11.45099,0,17.252189,"4::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,3,80,292,8,113,0,0,0,0,0,0,3.869863,1.934099,7.743057,0,17.23157,"4::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",4,3,81,241,11,239,0,0,0,0,0,0,7.302527,3.992307,13.357415,0,19.089384,"4::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,51,0,49,-0.3,0.5,-0.1,0.3,0,0,-0.2,-0.360893,-0.039107,0,7.341557,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,406,0,392,-0.34,0.461241,-0.14,0.45317,0,0,-0.2,-0.263446,-0.136554,0,12.02117,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,140,0,281,-0.33,0.473286,-0.09,0.502892,0,0.0499999687885079,-0.24,-0.337998,-0.142002,0.0024999968788517,10.339476,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Mease 2005",2005,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,151,0,162,-0.4,0.5,-0.1,0.5,0,0,-0.3,-0.410852,-0.189148,0,9.687278,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,101,0,106,-0.35,0.42,-0.13,0.45,0,0,-0.22,-0.338524,-0.101476,0,9.302648,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,1,0,101,0,102,-0.38,0.502494,-0.18,0.504975,0,0,-0.2,-0.33859,-0.06141,0,8.332601,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,2,0,273,0,136,-0.42,0.52,-0.16,0.36,0,0,-0.26,-0.346403,-0.173597,0,10.925291,"5::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,3,0,292,0,113,-0.35,0.5,-0.04,0.44,0,0,-0.31,-0.40935,-0.21065,0,10.270767,"5::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,3,0,233,0,222,-0.6,0.53,-0.12,0.47,0,0,-0.48,-0.571944,-0.388056,0,10.646535,"5::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,4,0,52,0,52,0.6,0.7,1.2,0.7,0,0,-0.6,-0.869066,-0.330934,0,4.015701,"5::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",5,4,0,100,0,100,0.7,0.6,1.1,0.6,0,0,-0.4,-0.566308,-0.233692,0,7.116976,"5::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"MCID in HAQ proportion of patients at 12 weeks",6,1,184,388,123,365,0,0,0,0,0,0,1.407258,1.177795,1.681426,0,50.982205,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"MCID in HAQ proportion of patients at 12 weeks",6,1,63,115,71,221,0,0,0,0,0,0,1.705205,1.323291,2.197343,0,25.123521,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"MCID in HAQ proportion of patients at 12 weeks",6,1,44,89,27,92,0,0,0,0,0,0,1.684561,1.151605,2.464165,0,11.165839,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"MCID in HAQ proportion of patients at 12 weeks",6,1,51,96,29,94,0,0,0,0,0,0,1.721983,1.205916,2.458899,0,12.728435,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,1,0,391,0,367,-0.39,0.553163,-0.19,0.535808,0,0,-0.2,-0.277532,-0.122468,0,15.498823,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,1,0,151,0,162,-0.4,0.5,-0.1,0.4,0,0,-0.3,-0.400767,-0.199233,0,14.103558,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,1,0,101,0,106,-0.37,0.44,-0.15,0.5,0,0,-0.22,-0.348154,-0.091846,0,12.412522,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,2,0,273,0,136,-0.47,0.6,-0.17,0.43,0,0,-0.3,-0.401432,-0.198568,0,14.062523,"7::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,3,0,101,0,104,0.5,1.004988,1,1.019804,0,0,-0.5,-0.777181,-0.222819,0,5.759206,"7::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,4,0,292,0,113,-0.36,0.53,0.01,0.49,0,0,-0.37,-0.478893,-0.261107,0,13.600081,"7::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,4,0,231,0,221,-0.63,0.55,-0.14,0.5,0,0,-0.49,-0.58683,-0.39317,0,14.346108,"7::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",7,5,0,100,0,100,0.7,0.6,1.1,0.6,0,0,-0.4,-0.566308,-0.233692,0,10.217179,"7::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"MCID in HAQ proportion of patients at 24 weeks",8,1,201,388,136,365,0,0,0,0,0,0,1.390331,1.179901,1.638291,0,37.581713,"8::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"MCID in HAQ proportion of patients at 24 weeks",8,1,44,89,24,92,0,0,0,0,0,0,1.895131,1.266476,2.835839,0,31.343193,"8::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"MCID in HAQ proportion of patients at 24 weeks",8,2,133,273,21,136,0,0,0,0,0,0,3.155067,2.090316,4.762175,0,31.075093,"8::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,1,0,49,0,45,1.1,7.4,-0.6,7.8,0,0,1.7,-1.380045,4.780045,0,7.568034,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,1,0,410,0,394,3.6,8.240371,2.2,8.58182,0,0,1.4,0.236267,2.563733,0,17.207008,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,1,0,136,0,151,1.6,10.1,1.2,10.2,0,0,0.4,-1.951205,2.751205,0,10.405237,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,1,0,101,0,106,4,8.2,1.8,9.8,0,0,2.2,-0.25722,4.65722,0,9.926034,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,1,0,100,0,102,3.13,9.38,3.27,9.857117,0,0,-0.14,-2.793143,2.513143,0,9.102648,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,2,0,273,0,136,3.66,9.44,1.4,8.6,0,0,2.26,0.431608,4.088392,0,13.12046,"9::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,3,0,292,0,113,3.18,11.2,0.4,11.39,0,0,2.78,0.318188,5.241812,0,9.905819,"9::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,3,0,233,0,222,5.3,9.9,1,7.6,0,0,4.3,2.682793,5.917207,0,14.369081,"9::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",9,4,0,100,0,100,3.8,11.1,-1.2,9.3,0,0,5,2.161772,7.838228,0,8.395679,"9::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,49,0,45,5.7,8.5,2.8,7.1,0,0,2.9,-0.257132,6.057132,0,6.113074,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,410,0,394,6.9,7.725348,3.3,8.077007,0,0,3.6,2.50673,4.69327,0,11.677517,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,140,0,281,6.8,9.465728,2.3,8.381527,0,0.943398144561756,4.5,2.650974,6.349026,0.890000059162564,9.488221,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Mease 2005",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,136,0,151,9.3,10,1.4,8.7,0,0,7.9,5.720513,10.079487,0,8.530725,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,101,0,106,5.4,7.5,2.3,6.8,0,0,3.1,1.146753,5.053247,0,9.181465,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,1,0,101,0,102,5.2,9.044888,2.1,9.089554,0,0,3.1,0.605373,5.594627,0,7.673877,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,2,0,273,0,136,7.1,8.43,1.8,6.1,0,0,5.3,3.867866,6.732134,0,10.725136,"10::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,3,0,101,0,104,9.1,9.3,1.4,8.4,0,0,7.7,5.27186,10.12814,0,7.849054,"10::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,4,0,292,0,113,7.19,9.23,0.63,7.68,0,0,6.56,4.791981,8.328019,0,9.728555,"10::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,4,0,233,0,222,8.7,7.6,2.7,5.9,0,0,6,4.75315,7.24685,0,11.257689,"10::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS).",10,5,0,100,0,100,9.1,9.3,1.1,8.4,0,0,8,5.543781,10.456219,0,7.774686,"10::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,1,0,391,0,367,4.1,8.548883,2.4,9.254864,0,0,1.7,0.429345,2.970655,0,19.157928,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,1,0,140,0,152,1.8,9.3,0.6,10.4,0,0,1.2,-1.059801,3.459801,0,12.381052,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,1,0,101,0,106,4.6,9.5,1.8,9.5,0,0,2.8,0.210933,5.389067,0,10.657473,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,2,0,273,0,136,4.51,9.94,0.7,9.9,0,0,3.81,1.770714,5.849286,0,13.696301,"11::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,3,0,101,0,104,53.6,9.044888,48.4,12.237647,0,0,5.2,2.260054,8.139946,0,9.115513,"11::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,4,0,292,0,113,3.84,10.79,-0.6,12.13,0,0,4.44,1.883912,6.996088,0,10.817517,"11::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,4,0,231,0,221,5.5,10.3,0.8,7.6,0,0,4.7,3.036198,6.363802,0,16.224157,"11::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",11,5,0,100,0,100,3.9,11.9,0.4,11.6,0,0,3.5,0.242861,6.757139,0,7.950059,"11::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,1,0,391,0,367,7.8,8.046007,4.3,8.280668,0,0,3.5,2.336487,4.663513,0,15.102399,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,1,0,140,0,152,9.3,10.1,1.4,9.6,0,0,7.9,5.63545,10.16455,0,11.593617,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,1,0,101,0,106,6.3,8.3,2.7,7.7,0,0,3.6,1.416228,5.783772,0,11.855849,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,2,0,273,0,136,8,9.16,2.1,7.2,0,0,5.9,4.273675,7.526325,0,13.685525,"12::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,3,0,101,0,104,45.1,11.054863,36.4,10.198039,0,0,8.7,5.786304,11.613696,0,9.606022,"12::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,4,0,292,0,113,7.83,9.41,0.67,8.72,0,0,7.16,5.223547,9.096453,0,12.668443,"12::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,4,0,231,0,221,9.5,8,2.5,6.2,0,0,7,5.683766,8.316234,0,14.657313,"12::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",12,5,0,100,0,100,7.7,9.8,1.3,8.2,0,0,6.4,3.895537,8.904463,0,10.830831,"12::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Radiographic progression (change from baseline) at 24 weeks",13,1,0,384,0,372,0.01,1.195981,0.25,1.127982,0,0,-0.206154,-0.349119,-0.06319,0,12.673534,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Radiographic progression (change from baseline) at 24 weeks",13,1,0,144,0,152,-0.2,2.53,1,2.62,0,0,-0.464538,-0.695555,-0.233521,0,12.610774,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Radiographic progression (change from baseline) at 24 weeks",13,1,0,101,0,106,0.1,0.904489,0.49,0.926607,0,0,-0.424258,-0.699897,-0.148619,0,12.568045,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Radiographic progression (change from baseline) at 24 weeks",13,2,0,273,0,136,0.06,0.991363,0.29,0.932952,0,0,-0.236098,-0.442451,-0.029744,0,12.631265,"13::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Radiographic progression (change from baseline) at 24 weeks",13,3,0,101,0,104,-0.05,2.009975,0.5,2.039608,0,0,-0.270592,-0.545675,0.004492,0,12.568621,"13::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Radiographic progression (change from baseline) at 24 weeks",13,4,0,292,0,113,-0.09,1.32,0.27,1.26,0,0,-0.275644,-0.493622,-0.057665,0,12.621886,"13::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Radiographic progression (change from baseline) at 24 weeks",13,4,0,237,0,237,-0.36,0.14,1.95,0.26,0,0,-11.045306,-11.773949,-10.316662,0,11.76581,"13::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Radiographic progression (change from baseline) at 24 weeks",13,5,0,100,0,100,-0.7,2.53,0.82,2.62,0,0,-0.587963,-0.871187,-0.304739,0,12.560065,"13::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Number of patients with serious adverse events at any time ",14,1,1,51,2,51,0,0,0,0,0,0,0.5,0.046793,5.342653,0,2.247879,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Number of patients with serious adverse events at any time ",14,1,16,429,13,423,0,0,0,0,0,0,1.213556,0.591049,2.491701,0,24.372556,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Number of patients with serious adverse events at any time ",14,1,2,140,3,281,0,0,0,0,0,0,1.338095,0.226181,7.916236,0,3.99166,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Number of patients with serious adverse events at any time ",14,1,6,153,7,162,0,0,0,0,0,0,0.907563,0.311987,2.640083,0,11.063005,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Number of patients with serious adverse events at any time ",14,1,5,101,2,106,0,0,0,0,0,0,2.623762,0.52079,13.21863,0,4.824202,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Number of patients with serious adverse events at any time ",14,1,1,106,1,105,0,0,0,0,0,0,0.990566,0.06278,15.62951,0,1.657545,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Number of patients with serious adverse events at any time ",14,1,0,72,1,24,0,0,0,0,0,0,0.114155,0.004803,2.712912,0,1.25668,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Number of patients with serious adverse events at any time ",14,2,21,273,6,136,0,0,0,0,0,0,1.74359,0.72057,4.219027,0,16.154227,"14::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"Number of patients with serious adverse events at any time ",14,3,0,30,1,30,0,0,0,0,0,0,0.333333,0.014119,7.869869,0,1.261905,"14::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Number of patients with serious adverse events at any time ",14,3,4,101,4,104,0,0,0,0,0,0,1.029703,0.264658,4.006256,0,6.834085,"14::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Number of patients with serious adverse events at any time ",14,4,7,292,7,113,0,0,0,0,0,0,0.386986,0.138864,1.078454,0,12.008723,"14::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Number of patients with serious adverse events at any time ",14,4,7,240,8,239,0,0,0,0,0,0,0.871354,0.321054,2.364895,0,12.653508,"14::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Number of patients with serious adverse events at any time ",14,5,1,52,1,52,0,0,0,0,0,0,1,0.064247,15.565023,0,1.674026,"14::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"(OR) Number of patients with serious adverse events at any time ",15,1,1,51,2,51,0,0,0,0,0,0,0.5,0.046793,5.342653,0,2.247879,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"(OR) Number of patients with serious adverse events at any time ",15,1,16,429,13,423,0,0,0,0,0,0,1.213556,0.591049,2.491701,0,24.372556,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"(OR) Number of patients with serious adverse events at any time ",15,1,2,140,3,281,0,0,0,0,0,0,1.338095,0.226181,7.916236,0,3.99166,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"(OR) Number of patients with serious adverse events at any time ",15,1,6,153,7,162,0,0,0,0,0,0,0.907563,0.311987,2.640083,0,11.063005,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"(OR) Number of patients with serious adverse events at any time ",15,1,5,101,2,106,0,0,0,0,0,0,2.623762,0.52079,13.21863,0,4.824202,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"(OR) Number of patients with serious adverse events at any time ",15,1,1,106,1,105,0,0,0,0,0,0,0.990566,0.06278,15.62951,0,1.657545,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"(OR) Number of patients with serious adverse events at any time ",15,1,0,72,1,24,0,0,0,0,0,0,0.114155,0.004803,2.712912,0,1.25668,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"(OR) Number of patients with serious adverse events at any time ",15,2,21,273,6,136,0,0,0,0,0,0,1.74359,0.72057,4.219027,0,16.154227,"15::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"(OR) Number of patients with serious adverse events at any time ",15,3,0,30,1,30,0,0,0,0,0,0,0.333333,0.014119,7.869869,0,1.261905,"15::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"(OR) Number of patients with serious adverse events at any time ",15,3,4,101,4,104,0,0,0,0,0,0,1.029703,0.264658,4.006256,0,6.834085,"15::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"(OR) Number of patients with serious adverse events at any time ",15,4,7,292,7,113,0,0,0,0,0,0,0.386986,0.138864,1.078454,0,12.008723,"15::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"(OR) Number of patients with serious adverse events at any time ",15,4,7,240,8,239,0,0,0,0,0,0,0.871354,0.321054,2.364895,0,12.653508,"15::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"(OR) Number of patients with serious adverse events at any time ",15,5,1,52,1,52,0,0,0,0,0,0,1,0.064247,15.565023,0,1.674026,"15::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Withdrawal due to adverse events",16,1,1,51,2,51,0,0,0,0,0,0,0.5,0.046793,5.342653,0,3.150467,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Withdrawal due to adverse events",16,1,22,429,13,423,0,0,0,0,0,0,1.668639,0.851841,3.268633,0,39.106502,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Withdrawal due to adverse events",16,1,3,140,3,281,0,0,0,0,0,0,2.007143,0.41037,9.817042,0,7.01585,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Withdrawal due to adverse events",16,1,6,153,1,162,0,0,0,0,0,0,6.352941,0.773737,52.16224,0,3.988146,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Withdrawal due to adverse events",16,1,2,101,2,106,0,0,0,0,0,0,1.049505,0.150679,7.309992,0,4.69289,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Withdrawal due to adverse events",16,1,2,106,1,105,0,0,0,0,0,0,1.981132,0.182397,21.518369,0,3.107375,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Withdrawal due to adverse events",16,1,0,72,0,24,0,0,0,0,0,0,NA,NA,NA,0,NA,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Mease 2014",2014,"Withdrawal due to adverse events",16,2,10,273,2,136,0,0,0,0,0,0,2.490842,0.553464,11.209943,0,7.813714,"16::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"Withdrawal due to adverse events",16,3,0,30,0,30,0,0,0,0,0,0,NA,NA,NA,0,NA,"16::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Mease 2004",2004,"Withdrawal due to adverse events",16,3,1,101,1,104,0,0,0,0,0,0,1.029703,0.065286,16.240709,0,2.323752,"16::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Withdrawal due to adverse events",16,4,6,292,5,113,0,0,0,0,0,0,0.464384,0.144594,1.491436,0,12.986036,"16::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Withdrawal due to adverse events",16,4,5,240,3,239,0,0,0,0,0,0,1.659722,0.401136,6.867193,0,8.766297,"16::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Withdrawal due to adverse events",16,5,2,52,1,52,0,0,0,0,0,0,2,0.187059,21.383682,0,3.148842,"16::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Withdrawal due to adverse events",16,5,5,100,1,100,0,0,0,0,0,0,5,0.594742,42.035049,0,3.90013,"16::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,20,51,8,51,0,0,0,0,0,0,2.5,1.214175,5.147527,0,5.100023,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,279,429,153,423,0,0,0,0,0,0,1.798026,1.556325,2.077263,0,9.57272,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,96,140,67,281,0,0,0,0,0,0,2.875906,2.268722,3.645593,0,9.01389,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,87,153,23,162,0,0,0,0,0,0,4.005115,2.676848,5.992475,0,7.671476,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,52,101,33,106,0,0,0,0,0,0,1.653765,1.176396,2.324846,0,8.205193,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,55,106,35,105,0,0,0,0,0,0,1.556604,1.122706,2.158193,0,8.320506,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,49,72,6,24,0,0,0,0,0,0,2.722222,1.337305,5.541366,0,5.179197,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,2,150,273,33,136,0,0,0,0,0,0,2.264402,1.651291,3.105157,0,8.411089,"17::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,3,22,30,4,30,0,0,0,0,0,0,5.5,2.153862,14.04454,0,3.824989,"17::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,3,60,101,16,104,0,0,0,0,0,0,3.861386,2.392494,6.232118,0,7.014002,"17::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,4,140,292,10,113,0,0,0,0,0,0,5.417808,2.962423,9.908322,0,5.976473,"17::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,4,181,241,52,239,0,0,0,0,0,0,3.451883,2.685193,4.437483,0,8.913289,"17::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,5,34,52,5,52,0,0,0,0,0,0,6.8,2.8877,16.012742,0,4.25809,"17::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,5,58,100,11,100,0,0,0,0,0,0,5.272727,2.94654,9.435356,0,6.15001,"17::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Torii 2010",2010,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,5,3,3,1,3,0,0,0,0,0,0,2.333333,0.624403,8.719443,0,2.389054,"17::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,1,288,429,191,423,0,0,0,0,0,0,1.486765,1.313172,1.683304,0,14.298311,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,1,86,153,24,162,0,0,0,0,0,0,3.794118,2.556398,5.631099,0,12.156506,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,1,58,101,32,106,0,0,0,0,0,0,1.902228,1.361187,2.65832,0,12.753523,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,2,164,273,32,136,0,0,0,0,0,0,2.553114,1.857571,3.509092,0,12.910226,"18::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,3,56,101,22,104,0,0,0,0,0,0,2.621062,1.739176,3.950127,0,11.998777,"18::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,4,165,292,14,113,0,0,0,0,0,0,4.56091,2.764893,7.523583,0,11.042584,"18::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,4,185,241,58,239,0,0,0,0,0,0,3.163185,2.502006,3.999087,0,13.622349,"18::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks.",18,5,54,100,16,100,0,0,0,0,0,0,3.375,2.079747,5.476927,0,11.217723,"18::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Enthesitis: resolution as LEI=0 at 12 weeks",19,1,124,265,79,241,0,0,0,0,0,0,1.427466,1.143574,1.781835,0,54.532653,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Enthesitis: resolution as LEI=0 at 12 weeks",19,1,18,36,29,70,0,0,0,0,0,0,1.206897,0.785652,1.854001,0,19.400772,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Enthesitis: resolution as LEI=0 at 12 weeks",19,1,19,54,16,57,0,0,0,0,0,0,1.253472,0.722376,2.175035,0,12.361134,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Enthesitis: resolution as LEI=0 at 12 weeks",19,1,36,76,14,65,0,0,0,0,0,0,2.199248,1.306177,3.702937,0,13.705442,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks",20,1,0,56,0,57,-0.8,1.795996,-0.8,1.81196,0,0,0,-0.665234,0.665234,0,28.457565,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks",20,1,0,73,0,63,-1.1,1.708801,-0.4,1.587451,0,0,-0.7,-1.254362,-0.145638,0,32.614744,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks",20,2,0,182,0,173,-1.8,1.8,-0.8,2,0,0,-1,-1.396492,-0.603508,0,38.927691,"20::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Enthesitis: resolution as LEI=0 at 24 weeks",21,1,125,265,78,241,0,0,0,0,0,0,1.457426,1.166589,1.820771,0,89.539684,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Enthesitis: resolution as LEI=0 at 24 weeks",21,1,18,54,11,57,0,0,0,0,0,0,1.727273,0.900603,3.312747,0,10.460316,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",22,1,0,56,0,57,-0.9,1.721162,-0.8,1.962957,0,0,-0.1,-0.780364,0.580364,0,25.147196,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",22,2,0,172,0,91,-1.9,1.85,-1.1,1.8,0,0,-0.8,-1.261748,-0.338252,0,35.894251,"22::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",22,3,0,181,0,172,-2.1,1.8,-1.1,2.1,0,0,-1,-1.408971,-0.591029,0,38.958553,"22::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Resolution of dactylitis as no dactylitis at 12 weeks",23,1,91,127,53,126,0,0,0,0,0,0,1.703462,1.350361,2.148892,0,57.24613,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Resolution of dactylitis as no dactylitis at 12 weeks",23,1,9,11,18,33,0,0,0,0,0,0,1.5,0.987676,2.278075,0,9.682769,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Resolution of dactylitis as no dactylitis at 12 weeks",23,1,11,18,15,28,0,0,0,0,0,0,1.140741,0.688657,1.889604,0,12.629699,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Resolution of dactylitis as no dactylitis at 12 weeks",23,1,27,58,19,58,0,0,0,0,0,0,1.421053,0.896703,2.252017,0,20.441402,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",24,1,0,49,0,45,-2.4,5.1,-1.4,4.3,0,0,-0.209498,-0.61533,0.196333,0,17.235548,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",24,1,0,18,0,28,-62.1,50.487424,-36.3,54.502477,0,0,-0.478562,-1.079452,0.122327,0,8.487454,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",24,1,0,56,0,55,-4,7.483315,-2,8.157818,0,0,-0.253837,-0.627465,0.119792,0,19.850899,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",24,2,0,130,0,115,-7.8,8.6,-2.8,7,0,0,-0.631764,-0.888929,-0.374599,0,35.710376,"24::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",24,3,0,52,0,52,0.4,3.5,1.4,2.8,0,0,-0.313193,-0.700015,0.073629,0,18.715724,"24::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Resolution of dactylitis as no dactylitis at 24 weeks",25,1,94,127,50,126,0,0,0,0,0,0,1.865197,1.469178,2.367963,0,70.605477,"25::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Resolution of dactylitis as no dactylitis at 24 weeks",25,1,14,18,7,28,0,0,0,0,0,0,3.111111,1.564474,6.186752,0,29.394523,"25::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",26,1,0,18,0,28,-76,46.244783,-33.7,51.327575,0,0,-0.841157,-1.459963,-0.222352,0,10.749298,"26::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",26,2,0,73,0,35,-47.36,55.32,-22,46.9,0,0,-0.477206,-0.88535,-0.069061,0,24.709304,"26::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",26,3,0,130,0,116,-8.2,8.9,-5,8.1,0,0,-0.373891,-0.626428,-0.121354,0,64.541398,"26::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,51,0,49,-15.4,25.6,0.2,23.1,0,0,-0.634243,-1.036441,-0.232045,0,9.187771,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,406,0,392,-2.3,2.049959,-0.9,2.517611,0,0,-0.610343,-0.752338,-0.468349,0,13.095499,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,140,0,281,-25.7,29.580399,-6.2,25.144582,0,0,-0.729085,-0.93779,-0.52038,0,12.235683,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,151,0,161,-23,27,1.6,24,0,0,-0.962531,-1.197215,-0.727847,0,11.852528,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,101,0,106,-27.9,23.9,-10.8,21,0,0,-0.758515,-1.040857,-0.476174,0,11.108429,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,105,0,104,-21.9,24.592682,-10.2,25.495098,0,0,-0.46545,-0.740317,-0.190583,0,11.227572,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in pain as measured by VAS or NRS at week 12.",27,2,0,273,0,136,-24.7,26.26,-9.9,21,0,0,-0.599541,-0.809354,-0.389727,0,12.21977,"27::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Improvement in pain as measured by VAS or NRS at week 12.",27,3,0,52,0,52,24.7,21.3,60.9,20.8,0,0,-1.706919,-2.158224,-1.255613,0,8.442109,"27::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Improvement in pain as measured by VAS or NRS at week 12.",27,3,0,100,0,100,3.4,2.1,6.6,2.3,0,0,-1.447534,-1.759554,-1.135514,0,10.630637,"27::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in pain as measured by VAS or NRS at week 24.",28,1,0,391,0,367,-2.6,2.011502,-1.4,1.948392,0,0,-0.605092,-0.750779,-0.459406,0,19.106894,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in pain as measured by VAS or NRS at week 24.",28,1,0,151,0,161,-24,28.3,0.6,24.1,0,0,-0.936071,-1.170087,-0.702056,0,17.032258,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in pain as measured by VAS or NRS at week 24.",28,1,0,101,0,106,-30.8,25.1,-13.4,25.1,0,0,-0.690688,-0.971378,-0.409998,0,15.803169,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in pain as measured by VAS or NRS at week 24.",28,2,0,273,0,136,-28.5,27.17,-11.2,21.8,0,0,-0.676799,-0.887724,-0.465874,0,17.618271,"28::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Improvement in pain as measured by VAS or NRS at week 24.",28,3,0,101,0,104,1.6,1.004988,2.8,1.019804,0,0,-1.180763,-1.4779,-0.883626,0,15.364563,"28::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Improvement in pain as measured by VAS or NRS at week 24.",28,4,0,100,0,100,3.5,2.1,6.5,2.3,0,0,-1.357063,-1.665075,-1.049052,0,15.074845,"28::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,112,211,45,211,0,0,0,0,0,0,2.488889,1.865075,3.321351,0,13.978208,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,45,68,18,140,0,0,0,0,0,0,5.147059,3.237843,8.182057,0,12.515559,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,34,69,3,69,0,0,0,0,0,0,11.333333,3.6526,35.165211,0,6.770168,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,23,68,5,67,0,0,0,0,0,0,4.532353,1.831039,11.218891,0,8.442993,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,30,77,12,82,0,0,0,0,0,0,2.662338,1.471652,4.816383,0,11.289474,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2018",2018,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,1,19,33,3,11,0,0,0,0,0,0,2.111111,0.770074,5.78748,0,7.641446,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,2,78,166,12,86,0,0,0,0,0,0,3.36747,1.944521,5.831696,0,11.708289,"29::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2000",2000,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,3,5,19,0,19,0,0,0,0,0,0,11,0.650483,186.015631,0,1.741155,"29::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,4,107,217,2,79,0,0,0,0,0,0,19.476959,4.925124,77.023825,0,5.366369,"29::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,4,116,196,27,198,0,0,0,0,0,0,4.340136,2.999943,6.279047,0,13.348288,"29::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005a",2005,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,5,15,22,0,17,0,0,0,0,0,0,24.26087,1.554386,378.663972,0,1.831707,"29::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",29,5,64,83,2,87,0,0,0,0,0,0,33.542169,8.481745,132.64689,0,5.366346,"29::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,1,124,211,56,211,0,0,0,0,0,0,2.214286,1.722201,2.846973,0,18.003248,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,1,41,69,1,69,0,0,0,0,0,0,41,5.8015,289.752639,0,7.026824,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,1,37,68,7,67,0,0,0,0,0,0,5.207983,2.499721,10.850446,0,15.033317,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,2,102,166,13,86,0,0,0,0,0,0,4.064875,2.428473,6.803948,0,16.608438,"30::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,3,23,66,3,62,0,0,0,0,0,0,7.20202,2.275632,22.793272,0,11.804576,"30::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,4,127,217,1,79,0,0,0,0,0,0,46.235023,6.573194,325.211379,0,7.047881,"30::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,4,127,196,26,198,0,0,0,0,0,0,4.934458,3.398798,7.163968,0,17.453496,"30::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",30,5,50,83,1,87,0,0,0,0,0,0,52.409639,7.408301,370.769245,0,7.02222,"30::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Genovese 2007",2007,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,49,0,46,2.6,7.1,2.3,6.7,0,0,0.3,-2.475025,3.075025,0,13.404117,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,410,0,394,5.7,9.270417,2.8,9.086633,0,0,2.9,1.631051,4.168949,0,19.938129,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,140,0,281,5,8.282512,1.5,8.381527,0,0,3.5,1.813975,5.186025,0,18.148002,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,140,0,148,6.5,11.1,0.6,8.4,0,0,5.9,3.616976,8.183024,0,15.476454,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,101,0,102,6,9.044888,3.3,9.089554,0,0,2.7,0.205373,5.194627,0,14.561865,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,2,0,233,0,222,8.4,9.86,2.2,7.6,0,0,6.2,4.586827,7.813173,0,18.471433,"31::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",32,1,0,391,0,367,6.8,9.051758,3.8,9.254864,0,0,3,1.695576,4.304424,0,35.306561,"32::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",32,1,0,143,0,151,7.1,10.2,0.1,9.6,0,0,7,4.73297,9.26703,0,30.762281,"32::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",32,2,0,231,0,221,9.2,9.77,2.3,7.8,0,0,6.9,5.27369,8.52631,0,33.931158,"32::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,1,0,391,0,367,4.1,8.548883,2.4,9.254864,0,0,1.7,0.429345,2.970655,0,19.157928,"33::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2005",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,1,0,140,0,152,1.8,9.3,0.6,10.4,0,0,1.2,-1.059801,3.459801,0,12.381052,"33::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,1,0,101,0,106,4.6,9.5,1.8,9.5,0,0,2.8,0.210933,5.389067,0,10.657473,"33::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2014",2014,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,2,0,273,0,136,4.51,9.94,0.7,9.9,0,0,3.81,1.770714,5.849286,0,13.696301,"33::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2004",2004,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,3,0,101,0,104,53.6,9.044888,48.4,12.237647,0,0,5.2,2.260054,8.139946,0,9.115513,"33::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,4,0,292,0,113,3.84,10.79,-0.6,12.13,0,0,4.44,1.883912,6.996088,0,10.817517,"33::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,4,0,231,0,221,5.5,10.3,0.8,7.6,0,0,4.7,3.036198,6.363802,0,16.224157,"33::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Antoni 2005b",2005,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",33,5,0,100,0,100,3.9,11.9,0.4,11.6,0,0,3.5,0.242861,6.757139,0,7.950059,"33::5","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,103,283,23,142,0,0,0,0,0,0,2.247043,1.499347,3.367599,0,30.450463,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,2,108,284,22,142,0,0,0,0,0,0,2.454545,1.625985,3.705319,0,29.388846,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,3,18,26,4,25,0,0,0,0,0,0,4.326923,1.700374,11.010677,0,5.713625,"1::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,3,11,21,5,23,0,0,0,0,0,0,2.409524,1.003325,5.786567,0,6.493761,"1::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,4,35,57,19,58,0,0,0,0,0,0,1.874423,1.228791,2.859283,0,27.953305,"1::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,117,283,39,142,0,0,0,0,0,0,1.5053,1.113846,2.034328,0,41.869639,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,2,114,284,38,142,0,0,0,0,0,0,1.5,1.103547,2.038879,0,40.312393,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,3,21,26,8,25,0,0,0,0,0,0,2.524038,1.38326,4.605619,0,10.499798,"2::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,3,12,21,7,23,0,0,0,0,0,0,1.877551,0.91355,3.858789,0,7.31817,"2::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,1,139,283,57,142,0,0,0,0,0,0,1.223607,0.969046,1.545039,0,49.641122,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,2,150,284,56,142,0,0,0,0,0,0,1.339286,1.06243,1.688287,0,50.358878,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,1,77,283,16,142,0,0,0,0,0,0,2.414753,1.465569,3.97868,0,32.096928,"4::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,2,80,284,15,142,0,0,0,0,0,0,2.666667,1.595953,4.455715,0,30.369534,"4::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,3,15,26,5,25,0,0,0,0,0,0,2.884615,1.232578,6.750896,0,11.070101,"4::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,3,10,21,3,23,0,0,0,0,0,0,3.650794,1.159916,11.490746,0,6.087757,"4::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,4,27,57,10,58,0,0,0,0,0,0,2.747368,1.468012,5.14167,0,20.375679,"4::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,1,101,283,33,142,0,0,0,0,0,0,1.53571,1.095957,2.151916,0,38.540486,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,2,102,284,32,142,0,0,0,0,0,0,1.59375,1.131846,2.244156,0,37.652647,"5::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,3,21,26,7,25,0,0,0,0,0,0,2.884615,1.496934,5.558698,0,11.848558,"5::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,3,11,21,9,23,0,0,0,0,0,0,1.338624,0.696892,2.571296,0,11.958308,"5::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 Weeks",6,1,124,283,41,142,0,0,0,0,0,0,1.517539,1.135623,2.027895,0,50.164737,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 Weeks",6,2,122,284,41,142,0,0,0,0,0,0,1.487805,1.112307,1.990065,0,49.835263,"6::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,1,0,264,0,133,-0.45,0.536187,-0.31,0.345977,0,0,-0.14,-0.227411,-0.052589,0,42.563496,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,2,0,268,0,133,-0.404,0.47475,-0.31,0.345977,0,0,-0.094,-0.17578,-0.01222,0,43.958141,"7::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,3,0,56,0,54,-0.99,0.72,-0.56,0.72,0,0,-0.43,-0.699145,-0.160855,0,13.478363,"7::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",8,1,0,257,0,126,-0.47,0.641249,-0.41,0.448999,0,0,-0.06,-0.170872,0.050872,0,49.999986,"8::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",8,2,0,258,0,126,-0.44,0.642495,-0.41,0.448999,0,0,-0.03,-0.140872,0.080872,0,50.000014,"8::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"MCID in HAQ proportion of patients at 24 weeks",9,1,151,283,75,142,0,0,0,0,0,0,1.010224,0.835561,1.221397,0,49.239788,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"MCID in HAQ proportion of patients at 24 weeks",9,2,158,284,75,142,0,0,0,0,0,0,1.053333,0.873717,1.269875,0,50.760212,"9::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",10,1,0,232,0,114,-0.554,0.624493,-0.526,0.43776,0,0,-0.028,-0.141644,0.085644,0,48.173267,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",10,2,0,238,0,114,-0.557,0.586235,-0.526,0.43776,0,0,-0.031,-0.140565,0.078565,0,51.826733,"10::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS) ",11,1,0,257,0,126,3.3,9.618732,3.3,6.734983,0,0,0,-1.663085,1.663085,0,50.000002,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS) ",11,2,0,256,0,127,2.8,9.6,3.3,6.761657,0,0,-0.5,-2.163085,1.163085,0,49.999998,"11::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks (SF-36 PCS) ",12,1,0,257,0,127,8,9.618732,6,6.761657,0,0,2,0.336915,3.663085,0,49.999997,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks (SF-36 PCS) ",12,2,0,256,0,126,7.8,9.6,6,6.734983,0,0,1.8,0.136915,3.463085,0,50.000003,"12::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Radiographic progression (change from baseline) at 52 weeks",13,1,0,226,0,108,-0.01,0.450999,0.08,0.311769,0,0,-0.09,-0.173154,-0.006846,0,58.139532,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Radiographic progression (change from baseline) at 52 weeks",13,2,0,225,0,108,-0.04,0.6,0.08,0.311769,0,0,-0.12,-0.217998,-0.022002,0,41.860468,"13::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Number of patients with serious adverse events at any time",14,1,17,283,8,142,0,0,0,0,0,0,1.066254,0.47159,2.410775,0,44.558501,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Number of patients with serious adverse events at any time",14,2,19,284,8,142,0,0,0,0,0,0,1.1875,0.532983,2.645779,0,46.206628,"14::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Number of patients with serious adverse events at any time",14,3,0,26,1,25,0,0,0,0,0,0,0.320988,0.013687,7.527945,0,2.979219,"14::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Number of patients with serious adverse events at any time",14,3,0,21,1,23,0,0,0,0,0,0,0.363636,0.015615,8.467964,0,2.992643,"14::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Number of patients with serious adverse events at any time",14,4,2,57,0,58,0,0,0,0,0,0,5.086207,0.249543,103.667619,0,3.263009,"14::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"(OR) Number of patients with serious adverse events at any time",15,1,17,283,8,142,0,0,0,0,0,0,1.070489,0.450462,2.543938,0,44.354052,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"(OR) Number of patients with serious adverse events at any time",15,2,19,284,8,142,0,0,0,0,0,0,1.200943,0.512389,2.814787,0,45.804848,"15::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"(OR) Number of patients with serious adverse events at any time",15,3,0,26,1,25,0,0,0,0,0,0,0.308176,0.01198,7.927375,0,3.15132,"15::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"(OR) Number of patients with serious adverse events at any time",15,3,0,21,1,23,0,0,0,0,0,0,0.348837,0.013462,9.039322,0,3.137145,"15::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"(OR) Number of patients with serious adverse events at any time",15,4,2,57,0,58,0,0,0,0,0,0,5.27027,0.247483,112.232786,0,3.552635,"15::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Withdrawal due to adverse events at any time",16,1,20,283,10,142,0,0,0,0,0,0,1.003534,0.482722,2.086252,0,42.933233,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Withdrawal due to adverse events at any time",16,2,16,284,9,142,0,0,0,0,0,0,0.888889,0.402846,1.961352,0,37.574477,"16::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Withdrawal due to adverse events at any time",16,3,1,26,3,25,0,0,0,0,0,0,0.320513,0.035671,2.879854,0,5.551211,"16::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Withdrawal due to adverse events at any time",16,3,1,21,0,23,0,0,0,0,0,0,3.272727,0.140539,76.211674,0,2.729182,"16::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Withdrawal due to adverse events at any time",16,4,7,57,2,58,0,0,0,0,0,0,3.561404,0.772437,16.420234,0,11.211897,"16::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,1,185,283,63,142,0,0,0,0,0,0,1.473442,1.203022,1.804649,0,35.338806,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,2,175,284,62,142,0,0,0,0,0,0,1.41129,1.146074,1.737881,0,33.725549,"17::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,3,22,26,9,25,0,0,0,0,0,0,2.350427,1.359129,4.064743,0,5.366976,"17::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,3,17,21,9,23,0,0,0,0,0,0,2.068783,1.193204,3.586866,0,5.317912,"17::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",17,4,45,57,31,58,0,0,0,0,0,0,1.47708,1.121882,1.944737,0,20.250756,"17::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",18,1,184,283,72,142,0,0,0,0,0,0,1.282293,1.067516,1.540281,0,42.792133,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",18,2,173,284,72,142,0,0,0,0,0,0,1.201389,0.996456,1.448469,0,41.109715,"18::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",18,3,22,26,14,25,0,0,0,0,0,0,1.510989,1.028996,2.218753,0,9.74294,"18::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",18,3,15,21,12,23,0,0,0,0,0,0,1.369048,0.850811,2.202947,0,6.355212,"18::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",19,1,185,283,81,142,0,0,0,0,0,0,1.146011,0.970702,1.35298,0,48.871213,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",19,2,197,284,81,142,0,0,0,0,0,0,1.216049,1.033852,1.430356,0,51.128787,"19::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Enthesitis: resolution as LEI=0 at 12 weeks",20,1,0,4,4,7,0,0,0,0,0,0,0.177778,0.011952,2.644356,0,32.589315,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Enthesitis: resolution as LEI=0 at 12 weeks",20,1,9,11,10,12,0,0,0,0,0,0,0.981818,0.673892,1.430448,0,67.410685,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Enthesitis: resolution as LEI=0 at 24 weeks",21,1,2,4,3,7,0,0,0,0,0,0,1.166667,0.317701,4.284257,0,6.76558,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Enthesitis: resolution as LEI=0 at 24 weeks",21,1,11,11,9,12,0,0,0,0,0,0,1.311404,0.923754,1.861729,0,93.23442,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Resolution of dactylitis as no dactylitis at 12 weeks",22,1,4,9,3,8,0,0,0,0,0,0,1.185185,0.373431,3.761504,0,65.489154,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Resolution of dactylitis as no dactylitis at 12 weeks",22,1,2,21,4,23,0,0,0,0,0,0,0.547619,0.111567,2.68796,0,34.510846,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Resolution of dactylitis as no dactylitis at 24 weeks",23,1,69,90,29,49,0,0,0,0,0,0,1.295402,0.999867,1.678291,0,37.888753,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Resolution of dactylitis as no dactylitis at 24 weeks",23,2,68,96,29,49,0,0,0,0,0,0,1.196839,0.91767,1.560935,0,36.016221,"23::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Van Mens 2019",2019,"Resolution of dactylitis as no dactylitis at 24 weeks",23,3,9,9,7,8,0,0,0,0,0,0,1.14,0.823733,1.577695,0,24.063523,"23::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Vieira-Sousa 2020",2020,"Resolution of dactylitis as no dactylitis at 24 weeks",23,3,6,21,4,23,0,0,0,0,0,0,1.642857,0.536927,5.026714,0,2.031503,"23::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",24,1,0,87,0,44,-110.2,211.731505,-128.8,177.771089,0,0,18.6,-50.237161,87.437161,0,48.17667,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",24,2,0,89,0,45,-119.1,195.283409,-128.8,179.779865,0,0,9.7,-56.671048,76.071048,0,51.82333,"24::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Resolution of dactylitis as no dactylitis at 52 weeks",25,1,70,84,32,40,0,0,0,0,0,0,1.041667,0.86826,1.249706,0,49.097675,"25::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Resolution of dactylitis as no dactylitis at 52 weeks",25,2,70,78,32,41,0,0,0,0,0,0,1.14984,0.961552,1.374998,0,50.902325,"25::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 52 weeks.",26,1,0,84,0,41,-129.3,192.468179,-132.2,167.121543,0,0,2.9,-62.757623,68.557623,0,54.739012,"26::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 52 weeks.",26,2,0,78,0,40,-115.2,229.625783,-132.2,165.070894,0,0,17,-55.205722,89.205722,0,45.260988,"26::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 12.",27,1,0,264,0,133,-24.9,25.996923,-16,18.4521,0,0,-8.9,-13.334892,-4.465108,0,37.340148,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 12.",27,2,0,268,0,133,-24.1,27.830199,-16,18.4521,0,0,-8.1,-12.675582,-3.524418,0,36.964909,"27::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Improvement in pain as measured by VAS or NRS at week 12.",27,3,0,56,0,54,-45.8,26.4,-23.1,20,0,0,-22.7,-31.432981,-13.967019,0,25.694944,"27::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 24.",28,1,0,257,0,126,-26.9,27.253073,-20.6,19.082453,0,0,-6.3,-11.012073,-1.587927,0,50,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 24.",28,2,0,258,0,126,-26.4,27.306043,-20.6,19.082453,0,0,-5.8,-10.512073,-1.087927,0,50,"28::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 52.",29,1,0,232,0,114,-31.1,27.416783,-27.2,19.218741,0,0,-3.9,-8.889254,1.089254,0,48.612213,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2019",2019,"Improvement in pain as measured by VAS or NRS at week 52.",29,2,0,238,0,114,-32.5,26.226323,-27.2,19.218741,0,0,-5.3,-10.152643,-0.447357,0,51.387787,"29::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",30,1,33,34,19,35,0,0,0,0,0,0,1.787926,1.311878,2.436719,0,100,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Baranauskaite 2012",2012,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",31,1,0,56,0,54,16.3,22,29.7,17.4,0,0,-13.4,-20.798578,-6.001422,0,100,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Ikonomidis 2013",2013,"Number of patients with serious adverse events at any time",1,1,0,10,0,10,0,0,0,0,0,0,NA,NA,NA,0,NA,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,NA,FALSE
"Ikonomidis 2013",2013,"Withdrawal due to adverse events",2,1,0,10,0,10,0,0,0,0,0,0,0,-0.174082,0.174082,0,100,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Ikonomidis 2013",2013,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",3,1,6,10,8,10,0,0,0,0,0,0,0.75,0.414331,1.357611,0,100,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,30,101,36,107,0,0,0,0,0,0,0.882838,0.591179,1.318389,0,18.380229,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,127,283,116,283,0,0,0,0,0,0,1.094828,0.905102,1.324322,0,81.619771,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,2,145,427,136,426,0,0,0,0,0,0,1.06368,0.87818,1.288362,0,100,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,3,64,140,189,431,0,0,0,0,0,0,1.042479,0.845226,1.285765,0,100,"1::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,39,101,43,107,0,0,0,0,0,0,0.960857,0.685628,1.346569,0,20.19189,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,132,283,143,283,0,0,0,0,0,0,0.923077,0.778957,1.093861,0,79.80811,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,2,171,427,183,426,0,0,0,0,0,0,0.932238,0.794793,1.093452,0,100,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,3,66,140,196,431,0,0,0,0,0,0,1.036662,0.8457,1.270743,0,100,"2::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,1,141,283,141,283,0,0,0,0,0,0,1,0.847597,1.179806,0,100,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,2,192,427,209,426,0,0,0,0,0,0,0.916509,0.794597,1.057126,0,100,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,3,70,140,235,431,0,0,0,0,0,0,0.917021,0.760814,1.105301,0,100,"3::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,1,82,283,99,283,0,0,0,0,0,0,0.828283,0.650332,1.054926,0,100,"4::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,2,63,140,194,431,0,0,0,0,0,0,0.999742,0.80975,1.234313,0,100,"4::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,1,32,101,32,107,0,0,0,0,0,0,1.059406,0.704749,1.59254,0,37.191605,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,1,100,283,135,283,0,0,0,0,0,0,0.740741,0.60689,0.904112,0,62.808395,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Araujo 2019",2019,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,2,11,24,18,23,0,0,0,0,0,0,0.585648,0.360459,0.951521,0,100,"5::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,3,67,140,209,431,0,0,0,0,0,0,0.98691,0.809306,1.203491,0,100,"5::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks",6,1,116,283,134,283,0,0,0,0,0,0,0.865672,0.718668,1.042745,0,100,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks",6,2,162,427,183,426,0,0,0,0,0,0,0.883173,0.750057,1.039913,0,100,"6::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks",6,3,74,140,237,431,0,0,0,0,0,0,0.961242,0.804313,1.148788,0,100,"6::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,1,0,101,0,107,-0.35,0.42,-0.39,0.51,0,0,0.04,-0.086678,0.166678,0,100,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,2,0,140,0,431,-0.33,0.473286,-0.26,0.415211,0,0,-0.07,-0.157652,0.017652,0,100,"7::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Proportion of patients achieving MCID in HAQ at 12 weeks",8,1,44,89,52,107,0,0,0,0,0,0,1.017286,0.763822,1.354859,0,100,"8::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Proportion of patients achieving MCID in HAQ at 12 weeks",8,2,63,115,161,318,0,0,0,0,0,0,1.082042,0.887344,1.319459,0,100,"8::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",9,1,0,101,0,107,-0.37,0.44,-0.44,0.53,0,0,0.07,-0.062091,0.202091,0,0.190239,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",9,1,0,283,0,283,-0.56,0.035,-0.63,0.035,0,0,0.07,0.064233,0.075767,0,99.809761,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"McInnes 2023",2023,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",9,2,0,140,0,431,-0.34,0.591608,-0.3,0.415211,0,0,-0.04,-0.145547,0.065547,0,100,"9::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Proportion of patients achieving MCID in HAQ at 24 weeks",10,1,44,89,52,107,0,0,0,0,0,0,1.017286,0.763822,1.354859,0,15.998484,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Proportion of patients achieving MCID in HAQ at 24 weeks",10,1,166,254,168,252,0,0,0,0,0,0,0.980315,0.865075,1.110906,0,84.001516,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Proportion of patients achieving MCID in HAQ at 24 weeks",10,2,64,115,170,318,0,0,0,0,0,0,1.041023,0.858557,1.262268,0,100,"10::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",11,1,0,283,0,283,-0.62,0.035,-0.68,0.035,0,0,0.06,0.054233,0.065767,0,100,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"McInnes 2020",2020,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",11,2,0,318,0,363,-0.56,0.534977,-0.58,0.571577,0,0,0.02,-0.063154,0.103154,0,100,"11::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",11,3,0,140,0,431,-0.41,0.591608,-0.34,0.415211,0,0,-0.07,-0.175547,0.035547,0,100,"11::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Proportion of patients achieving MCID in HAQ at 52 weeks",12,1,168,254,164,252,0,0,0,0,0,0,1.016324,0.895844,1.153007,0,100,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Proportion of patients achieving MCID in HAQ at 52 weeks",12,2,218,427,234,426,0,0,0,0,0,0,0.929442,0.81893,1.054867,0,100,"12::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Proportion of patients achieving MCID in HAQ at 52 weeks",12,3,68,115,182,318,0,0,0,0,0,0,1.033158,0.863651,1.235934,0,100,"12::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",13,1,0,101,0,107,4,8.2,2.9,11.4,0,0,1.1,-1.587597,3.787597,0,100,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS). ",14,1,0,101,0,107,5.4,7.5,6.2,9.2,0,0,-0.8,-3.07555,1.47555,0,100,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS). ",14,2,0,140,0,431,6.8,9.465728,6.3,8.304216,0,0,0.5,-1.253045,2.253045,0,100,"14::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",15,1,0,101,0,107,4.6,9.5,4.6,11.9,0,0,0,-2.918321,2.918321,0,26.98314,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",15,1,0,283,0,283,3.8,9.5,4.5,11.9,0,0,-0.7,-2.474058,1.074058,0,73.01686,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",16,1,0,101,0,107,6.3,8.3,7.7,9.8,0,0,-1.4,-3.863363,1.063363,0,26.950634,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",16,1,0,283,0,283,9.04,8.3,9.9,9.8,0,0,-0.86,-2.356252,0.636252,0,73.049366,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",16,2,0,140,0,431,7.3,9.465728,7.3,8.304216,0,0,0,-1.753045,1.753045,0,100,"16::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks (SF-36 MCS). ",17,1,0,246,0,240,4.77,10.288958,5.23,10.224676,0,0,-0.46,-2.283858,1.363858,0,100,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks (SF-36 PCS). ",18,1,0,246,0,240,9.55,8.218619,10.07,8.148757,0,0,-0.52,-1.975202,0.935202,0,100,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks (SF-36 PCS). ",18,2,0,140,0,431,9,10.648944,8.1,10.38027,0,0,0.9,-1.117906,2.917906,0,100,"18::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Radiographic progression (change from baseline) at 52 weeks",19,1,0,135,0,420,-0.12,1.394274,0.1,1.434573,0,0,-0.22,-0.492287,0.052287,0,100,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Radiographic progression (change from baseline) at 24 weeks",20,1,0,101,0,107,0.1,0.904489,0.17,0.827526,0,0,-0.07,-0.306011,0.166011,0,100,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Number of patients with serious adverse events at any time",21,1,5,101,6,107,0,0,0,0,0,0,0.882838,0.278076,2.802846,0,39.371583,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Number of patients with serious adverse events at any time",21,1,24,283,10,283,0,0,0,0,0,0,2.4,1.169295,4.926046,0,60.628417,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Number of patients with serious adverse events at any time",21,2,28,427,33,426,0,0,0,0,0,0,0.846498,0.520991,1.375376,0,100,"21::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Number of patients with serious adverse events at any time",21,3,5,140,17,431,0,0,0,0,0,0,0.905462,0.340263,2.409497,0,100,"21::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Withdrawal due to adverse events",22,1,2,101,2,107,0,0,0,0,0,0,1.059406,0.152087,7.379598,0,17.823133,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Withdrawal due to adverse events",22,1,13,283,7,283,0,0,0,0,0,0,1.857143,0.75208,4.58592,0,82.176867,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Withdrawal due to adverse events",22,2,32,427,17,426,0,0,0,0,0,0,1.877945,1.059148,3.329728,0,100,"22::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Araujo 2019",2019,"Withdrawal due to adverse events",22,3,0,24,1,23,0,0,0,0,0,0,0.32,0.013696,7.476637,0,100,"22::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Withdrawal due to adverse events",22,4,7,140,12,431,0,0,0,0,0,0,1.795833,0.721104,4.472335,0,100,"22::4","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,1,52,101,61,107,0,0,0,0,0,0,0.9031,0.702755,1.160561,0,16.762282,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,1,196,283,190,283,0,0,0,0,0,0,1.031579,0.921762,1.154479,0,83.237718,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,2,265,427,268,426,0,0,0,0,0,0,0.98649,0.88905,1.09461,0,100,"23::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,3,96,140,268,431,0,0,0,0,0,0,1.102772,0.964325,1.261095,0,100,"23::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,1,58,101,62,107,0,0,0,0,0,0,0.991057,0.785126,1.251002,0,17.341183,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,1,204,283,195,283,0,0,0,0,0,0,1.046154,0.940289,1.163937,0,82.658817,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,2,273,427,302,426,0,0,0,0,0,0,0.901856,0.821201,0.990434,0,100,"24::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,3,99,140,282,431,0,0,0,0,0,0,1.080775,0.952085,1.226859,0,100,"24::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",25,1,195,283,197,283,0,0,0,0,0,0,0.989848,0.886935,1.104701,0,100,"25::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",25,2,265,427,285,426,0,0,0,0,0,0,0.927647,0.839534,1.025008,0,100,"25::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",25,3,102,140,307,431,0,0,0,0,0,0,1.022848,0.909393,1.150457,0,100,"25::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Enthesitis: resolution as LEI=0 at 12 weeks",26,1,19,54,19,68,0,0,0,0,0,0,1.259259,0.744136,2.130973,0,100,"26::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Enthesitis: resolution as LEI=0 at 12 weeks",26,2,18,36,72,143,0,0,0,0,0,0,0.993056,0.689402,1.430456,0,100,"26::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks",27,1,0,56,0,70,-0.8,1.795996,-0.9,1.756986,0,0,0.1,-0.525041,0.725041,0,100,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Enthesitis: resolution as LEI=0 at 24 weeks",28,1,18,54,29,68,0,0,0,0,0,0,0.781609,0.489892,1.247037,0,14.685983,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Enthesitis: resolution as LEI=0 at 24 weeks",28,1,81,147,95,159,0,0,0,0,0,0,0.922234,0.759736,1.119489,0,85.314017,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Araujo 2019",2019,"Enthesitis: resolution as LEI=0 at 24 weeks",28,2,12,24,18,23,0,0,0,0,0,0,0.638889,0.405596,1.006369,0,100,"28::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Enthesitis: resolution as LEI=0 at 24 weeks",28,3,115,264,116,234,0,0,0,0,0,1.41443596695058,0.878723,0.727719,1.061059,2.00062910460341,100,"28::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",29,1,0,56,0,70,-0.9,1.721162,-1.3,1.756986,0,0,0.4,-0.210427,1.010427,0,100,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",29,2,0,264,0,234,-1.6,1.6,-1.6,1.6,0,0,0,-0.281561,0.281561,0,100,"29::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Enthesitis: resolution as LEI=0 at 52 weeks",30,1,84,147,98,159,0,0,0,0,0,0,0.927114,0.769672,1.116762,0,100,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Enthesitis: resolution as LEI=0 at 52 weeks",30,2,146,264,142,234,0,0,0,0,0,0.0760324864785907,0.911332,0.784662,1.05845,0.005780939000117,100,"30::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Enthesitis: resolution as LEI=0 at 52 weeks",30,3,21,36,87,143,0,0,0,0,0,0,0.958812,0.706201,1.301784,0,100,"30::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 52 weeks.",31,1,0,121,0,141,-2.02,1.276,-1.93,1.341801,0,0,-0.09,-0.407399,0.227399,0,100,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 52 weeks.",31,2,0,264,0,234,-2.1,1.7,-1.8,1.6,0,0,-0.3,-0.589963,-0.010037,0,100,"31::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Resolution of dactylitis as no dactylitis at 12 weeks",32,1,11,18,29,39,0,0,0,0,0,0,0.821839,0.544304,1.240887,0,100,"32::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Resolution of dactylitis as no dactylitis at 12 weeks",32,2,9,11,44,56,0,0,0,0,0,0,1.041322,0.763492,1.420254,0,100,"32::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",33,1,0,18,0,39,-62.1,50.487424,-72.8,54.955982,0,0,10.7,-18.308129,39.708129,0,100,"33::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Resolution of dactylitis as no dactylitis at 24 weeks",34,1,14,18,31,39,0,0,0,0,0,0,0.978495,0.7293,1.312836,0,16.656264,"34::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Resolution of dactylitis as no dactylitis at 24 weeks",34,1,54,58,37,42,0,0,0,0,0,0,1.05685,0.926717,1.205257,0,83.343736,"34::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",35,1,0,18,0,39,-76,46.244783,-75.4,50.584484,0,0,-0.6,-27.216571,26.016571,0,100,"35::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Resolution of dactylitis as no dactylitis at 52 weeks",36,1,47,58,35,42,0,0,0,0,0,0,0.972414,0.809123,1.168659,0,100,"36::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Resolution of dactylitis as no dactylitis at 52 weeks",36,2,96,137,97,130,0,0,0,0,0,0,0.939123,0.809589,1.089382,0,100,"36::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Resolution of dactylitis as no dactylitis at 52 weeks",36,3,8,11,45,56,0,0,0,0,0,0,0.905051,0.616241,1.329215,0,100,"36::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 52 weeks.",37,1,0,47,0,35,-48.89,67.562476,-52.28,68.005337,0,0,3.39,-26.286214,33.066214,0,100,"37::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in pain as measured by VAS or NRS at week 12.",38,1,0,101,0,107,-27.9,23.9,-29,26.2,0,0,1.1,-5.709534,7.909534,0,100,"38::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in pain as measured by VAS or NRS at week 12.",38,2,0,140,0,431,-25.7,29.580399,-23.6,26.988701,0,0,-2.1,-7.622788,3.422788,0,100,"38::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in pain as measured by VAS or NRS at week 24.",39,1,0,101,0,107,-30.8,25.1,-31,28.8,0,0,0.2,-7.130763,7.530763,0,0.128354,"39::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in pain as measured by VAS or NRS at week 24.",39,1,0,283,0,283,-31.33,1.591,-32.29,1.599,0,0,0.96,0.697196,1.222804,0,99.871646,"39::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in pain as measured by VAS or NRS at week 24.",39,2,0,140,0,431,-27.2,31.946831,-27,29.064755,0,0,-0.2,-6.160998,5.760998,0,100,"39::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in pain as measured by VAS or NRS at week 52.",40,1,0,283,0,283,-36.54,1.621,-37.21,1.623,0,0,0.67,0.402748,0.937252,0,100,"40::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in pain as measured by VAS or NRS at week 52.",40,2,0,140,0,431,-32.7,29.580399,-30.4,29.064755,0,2.86530975581223,-2.3,-7.915904,3.315904,8.20999999675272,100,"40::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE
"Mease 2017a",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",41,1,23,68,55,73,0,0,0,0,0,0,0.44893,0.314017,0.641808,0,44.238923,"41::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",41,1,172,283,233,283,0,0,0,0,0,0,0.738197,0.662599,0.822421,0,55.761077,"41::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",41,2,45,68,168,217,0,0,0,0,0,0,0.854779,0.710772,1.027963,0,100,"41::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017a",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",42,1,37,68,52,73,0,0,0,0,0,0,0.763857,0.587866,0.992537,0,12.137784,"42::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",42,1,195,283,227,283,0,0,0,0,0,0,0.859031,0.779356,0.946851,0,87.862216,"42::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",42,2,40,68,176,217,0,0,0,0,0,0,0.725267,0.588496,0.893825,0,100,"42::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2020",2020,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks.",43,1,194,283,222,283,0,0,0,0,0,0,0.873874,0.790884,0.965573,0,100,"43::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2020",2020,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks.",43,2,123,202,170,215,0,0,0,0,0,0,0.770093,0.676101,0.877152,0,100,"43::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks.",43,3,45,68,177,217,0,0,0,0,0,0,0.811316,0.676779,0.972598,0,100,"43::3","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",44,1,0,140,0,431,5,8.282512,3.9,8.304216,0,0,1.1,-0.480174,2.680174,0,100,"44::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",45,1,0,140,0,431,5.2,9.465728,4.5,8.304216,0,0,0.7,-1.053045,2.453045,0,100,"45::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2023",2023,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 52 weeks.",46,1,0,140,0,431,5.5,9.465728,5,14.532378,0,0,0.5,-1.58347,2.58347,0,100,"46::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,1,35,106,30,107,0,0,0,0,0,0,1.177673,0.783898,1.769253,0,100,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks",1,2,161,429,161,429,0,0,0,0,0,0.0881236433773367,1,0.841425,1.188461,0.007765776522096,100,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,1,45,106,42,107,0,0,0,0,0,0,1.081536,0.78257,1.494717,0,100,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks",2,2,190,429,225,429,0,0,0,0,0,0.0710705185912563,0.844444,0.734697,0.970586,0.0050510186128301,100,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,1,43,106,48,107,0,0,0,0,0,0,0.904285,0.662046,1.235157,0,100,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 52 weeks",3,2,220,429,256,429,0,0,0,0,0,0.0616045519349291,0.859375,0.761697,0.969579,0.0037951208191033,100,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,1,27,106,28,107,0,0,0,0,0,0,0.973383,0.617354,1.534733,0,100,"4::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 12 weeks",4,2,107,429,106,429,0,0,0,0,0,0.118840956451567,1.009434,0.799723,1.274137,0.0141231729303231,100,"4::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,1,38,106,28,107,0,0,0,0,0,0,1.369946,0.911342,2.059327,0,100,"5::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 24 weeks",5,2,143,429,157,429,0,0,0,0,0,0.0933051446504863,0.910828,0.758647,1.093536,0.0087058500182481,100,"5::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks",6,1,42,106,40,107,0,0,0,0,0,0,1.059906,0.754678,1.488582,0,100,"6::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Disease activity as measured by MDA-PsA criteria or by DAS 28 or by DAS at 52 weeks",6,2,170,429,192,429,0,0,0,0,0,0.0802128577483599,0.885417,0.756657,1.036087,0.0064341025481586,100,"6::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,1,0,101,0,103,-0.38,0.502494,-0.35,0.507445,0,0,-0.03,-0.16859,0.10859,0,100,"7::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 12 weeks",7,2,0,406,0,404,-0.34,0.461241,-0.42,0.511218,0,0,0.08,0.012933,0.147067,0,100,"7::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"MCID in HAQ proportion of patients at 12 weeks",8,1,51,96,51,96,0,0,0,0,0,0,1,0.766642,1.304389,0,100,"8::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"MCID in HAQ proportion of patients at 12 weeks",8,2,184,388,215,372,0,0,0,0,0,0,0.820523,0.71613,0.940132,0,100,"8::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",9,1,0,99,0,100,-0.42,0.497494,-0.45,0.5,0,0,0.03,-0.10859,0.16859,0,100,"9::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 24 weeks",9,2,0,391,0,390,-0.39,0.553163,-0.51,0.502228,0,0,0.12,0.045901,0.194099,0,100,"9::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"MCID in HAQ proportion of patients at 24 weeks",10,1,201,388,223,372,0,0,0,0,0,0,0.864176,0.761164,0.98113,0,100,"10::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",11,1,0,94,0,96,-0.45,0.484768,-0.54,0.489898,0,0,0.09,-0.04859,0.22859,0,100,"11::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Physical function as measured by the HAQ or by the proportion of patients achieving the MCID of the HAQ which is defined as 0.35 or by the MHAQ at 52 weeks",11,2,0,361,0,370,-0.43,0.531381,-0.54,0.538008,0,0,0.11,0.032477,0.187523,0,100,"11::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"MCID in HAQ proportion of patients at 52 weeks",12,1,200,388,224,372,0,0,0,0,0,0,0.856038,0.75394,0.971962,0,100,"12::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",13,1,0,100,0,102,3.13,9.38,4.35,9.18045,0,0,-1.22,-3.78008,1.34008,0,100,"13::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 MCS). ",13,2,0,410,0,405,3.6,8.240371,3.9,8.701524,0,0,-0.3,-1.463785,0.863785,0,100,"13::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS). ",14,1,0,101,0,102,5.2,9.044888,5.2,8.079604,0,0,0,-2.360109,2.360109,0,100,"14::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 12 weeks. (SF-36 PCS). ",14,2,0,410,0,405,6.8,7.725348,7.9,7.677816,0,0,-1.1,-2.157502,-0.042498,0,100,"14::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",15,1,0,98,0,100,4.58,9.454018,5.7,9.27,0,0,-1.12,-3.72856,1.48856,0,100,"15::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 MCS). ",15,2,0,391,0,390,4.1,8.548883,4.7,9.040103,0,0,-0.6,-1.834095,0.634095,0,100,"15::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",16,1,0,98,0,100,6.26,7.800802,6.72,7.73,0,0,-0.46,-2.623496,1.703496,0,100,"16::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 24 weeks. (SF-36 PCS). ",16,2,0,391,0,390,7.8,8.046007,9.8,8.035647,0,0,-2,-3.127855,-0.872145,0,100,"16::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 MCS). ",17,1,0,94,0,96,4.81,10.073479,4.82,9.915534,0,0,-0.01,-2.852735,2.832735,0,100,"17::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 MCS). ",17,2,0,364,0,371,4.3,8.731617,5.2,9.305496,0,0,-0.9,-2.204306,0.404306,0,100,"17::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 PCS). ",18,1,0,94,0,96,6.8,8.725824,7.7,8.818163,0,0,-0.9,-3.394627,1.594627,0,100,"18::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Health-related quality of life as measured by the SF-36 or by the PSAQOL at 52 weeks. (SF-36 PCS). ",18,2,0,364,0,371,8.9,8.731617,10.8,8.32597,0,0,-1.9,-3.133851,-0.666149,0,100,"18::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Radiographic progression (change from baseline) at 24 weeks",19,1,0,384,0,391,0.01,1.195981,-0.04,1.156614,0,0,0.05,-0.115687,0.215687,0,100,"19::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Radiographic progression (change from baseline) at 52 weeks",20,1,0,95,0,98,-0.07,0.682276,0.01,0.692965,0,0,-0.08,-0.274027,0.114027,0,100,"20::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Radiographic progression (change from baseline) at 52 weeks",20,2,0,337,0,353,-0.06,1.285029,-0.03,1.315181,0,0,-0.03,-0.224027,0.164027,0,100,"20::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Number of patients with serious adverse events at any time",21,1,9,106,8,107,0,0,0,0,0,0,1.135613,0.455418,2.831721,0,100,"21::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Number of patients with serious adverse events at any time",21,2,16,429,14,429,0,0,0,0,0,0,1.142857,0.564877,2.312225,0,100,"21::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Withdrawal due to adverse events",22,1,4,106,6,107,0,0,0,0,0,0,0.672956,0.195462,2.316914,0,100,"22::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Withdrawal due to adverse events",22,2,23,429,21,429,0,0,0,0,0,0.294008035200165,1.095238,0.61554,1.948771,0.0864407247622616,100,"22::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,1,55,106,54,107,0,0,0,0,0,0,1.028127,0.790858,1.336581,0,100,"23::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 12 weeks",23,2,279,429,303,430,0,0,0,0,0,0,0.922938,0.841385,1.012397,0,100,"23::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,1,67,106,62,107,0,0,0,0,0,0,1.09084,0.877921,1.355397,0,100,"24::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 24 weeks",24,2,288,429,315,430,0,0,0,0,0,0,0.916417,0.83969,1.000154,0,100,"24::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",25,1,64,106,73,107,0,0,0,0,0,0,0.884983,0.723654,1.082279,0,100,"25::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",25,2,294,429,319,430,0,0,0,0,0,0,0.923778,0.848525,1.005706,0,100,"25::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Enthesitis: resolution as LEI=0 at 12 weeks",26,1,36,76,25,75,0,0,0,0,0,0,1.421053,0.954231,2.116248,0,100,"26::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Enthesitis: resolution as LEI=0 at 12 weeks",26,2,124,265,128,270,0,0,0,0,0,0,0.987028,0.82474,1.181251,0,100,"26::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 12 weeks.",27,1,0,73,0,70,-1.1,1.708801,-0.8,1.67332,0,0,-0.3,-0.854362,0.254362,0,100,"27::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Enthesitis: resolution as LEI=0 at 24 weeks",28,1,125,265,145,270,0,0,0,0,0,0,0.878334,0.741893,1.039868,0,100,"28::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 24 weeks.",29,1,0,71,0,72,-1.3,1.853753,-1.3,1.781909,0,0,0,-0.5961,0.5961,0,100,"29::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Enthesitis: resolution as LEI=0 at 52 weeks",30,1,42,76,42,75,0,0,0,0,0,0,0.986842,0.742202,1.312119,0,100,"30::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Enthesitis: resolution as LEI=0 at 52 weeks",30,2,143,265,160,270,0,0,0,0,0,0,0.910613,0.784694,1.056739,0,100,"30::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in enthesitis in patients with enthesitis at baseline as measured by the LEI or by the MASES at 52 weeks.",31,1,0,67,0,67,-1.6,1.637071,-1.7,1.555217,0,0,0.1,-0.44068,0.64068,0,100,"31::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Resolution of dactylitis as no dactylitis at 12 weeks",32,1,27,58,21,61,0,0,0,0,0,0,1.352217,0.868516,2.105304,0,100,"32::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Resolution of dactylitis as no dactylitis at 12 weeks",32,2,91,127,100,136,0,0,0,0,0,0,0.974488,0.839776,1.13081,0,100,"32::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 12 weeks.",33,1,0,56,0,58,-4,7.483315,-3.5,7.615773,0,0,-0.5,-3.271808,2.271808,0,100,"33::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Resolution of dactylitis as no dactylitis at 24 weeks",34,1,94,127,104,136,0,0,0,0,0,0,0.967898,0.842326,1.112191,0,100,"34::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 24 weeks.",35,1,0,53,0,58,-5.4,7.498513,-5.2,7.691931,0,0,-0.2,-3.02738,2.62738,0,100,"35::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Resolution of dactylitis as no dactylitis at 52 weeks",36,1,40,58,39,61,0,0,0,0,0,0,1.078691,0.835399,1.392838,0,100,"36::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Resolution of dactylitis as no dactylitis at 52 weeks",36,2,94,127,102,136,0,0,0,0,0,0,0.986877,0.856627,1.13693,0,100,"36::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in dactylitis in patients with dactylitis at baseline as measured by a simple quantitative scoring of dactylitis or by LDI or by LDI basic at 52 weeks.",37,1,0,52,0,54,-6.1,4.831439,-7.4,4.776505,0,0,1.3,-0.529603,3.129603,0,100,"37::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in pain as measured by VAS or NRS at week 12.",38,1,0,105,0,107,-21.9,24.592682,-21.5,23.791385,0,0,-0.016476,-0.285714,0.252763,0,100,"38::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in pain as measured by VAS or NRS at week 12.",38,2,0,406,0,404,-2.3,2.049959,-2.3,2.556091,0,0,0,-0.137733,0.137733,0,100,"38::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in pain as measured by VAS or NRS at week 24.",39,1,0,391,0,390,-2.6,2.011502,-3,2.51114,0,0,0.4,0.080839,0.719161,0,100,"39::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in pain as measured by VAS or NRS at week 52.",40,1,0,362,0,370,-2.9,1.934986,-3.3,2.445491,0,0,0.4,0.080903,0.719097,0,100,"40::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",41,1,30,77,35,82,0,0,0,0,0,0,0.912801,0.626988,1.328903,0,100,"41::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 12 weeks.",41,2,112,211,134,214,0,0,0,0,0,0,0.847705,0.719672,0.998515,0,100,"41::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",42,1,41,77,38,82,0,0,0,0,0,0,1.149009,0.840105,1.571495,0,100,"42::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 24 weeks.",42,2,124,211,137,214,0,0,0,0,0,0,0.917978,0.789161,1.067824,0,100,"42::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks.",43,1,43,77,46,82,0,0,0,0,0,0,0.995483,0.755475,1.311738,0,100,"43::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in psoriasis in patients with psoriasis at baseline as measured by the PASI75 response at 52 weeks.",43,2,129,211,140,214,0,0,0,0,0,0,0.934529,0.808288,1.080487,0,100,"43::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",44,1,0,101,0,102,6,9.044888,7,8.584579,0,0,-1,-3.426321,1.426321,0,100,"44::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 12 weeks.",44,2,0,410,0,404,5.7,9.270417,6.3,9.201928,0,0,-0.6,-1.868998,0.668998,0,100,"44::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",45,1,0,99,0,100,6.5,9.054386,7.9,8.9,0,0,-1.4,-3.894781,1.094781,0,100,"45::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 24 weeks.",45,2,0,391,0,390,6.8,9.051758,7.9,9.040103,0,0,-1.1,-2.368837,0.168837,0,100,"45::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Mease 2017b",2017,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 52 weeks.",46,1,0,94,0,96,6.9,9.404499,8.5,9.308061,0,0,-1.6,-4.26108,1.06108,0,100,"46::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"McInnes 2021",2021,"Improvement in fatigue as measured by FACIT-F scale or by the FATIGUE VAS at 52 weeks.",46,2,0,364,0,370,7.6,9.216707,8.9,9.292864,0,0,-1.3,-2.63906,0.03906,0,100,"46::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,FALSE,TRUE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE
"Atteno 2010",2010,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",1,NA,24,34,26,36,0,0,0,0,0,0,0.977376,0.726344,1.315165,0,100,"1::overall","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Atteno 2010",2010,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks.",1,NA,24,34,22,30,0,0,0,0,0,0,0.962567,0.708817,1.307157,0,100,"1::overall","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Atteno 2010",2010,"Clinical improvement as measured by ACR20 response criteria or by the EULAR moderate response criteria or by PsARC criteria at 52 weeks",1,NA,26,36,22,30,0,0,0,0,0,0,0.984848,0.732532,1.324073,0,100,"1::overall","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",1,1,33,117,0,44,0,0,0,0,0,0,25.550847,1.599113,408.254926,0,8.52702,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",1,1,52,113,12,118,0,0,0,0,0,0,4.525074,2.553347,8.019393,0,41.394444,"1::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",1,2,52,175,2,69,0,0,0,0,0,0,10.251429,2.567331,40.934254,0,22.578771,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 12 weeks stratified for sex",1,2,53,128,3,121,0,0,0,0,0,0,16.700521,5.360872,52.026494,0,27.499765,"1::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",2,1,33,117,2,44,0,0,0,0,0,0,6.205128,1.553979,24.777431,0,10.459538,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",2,1,63,113,7,118,0,0,0,0,0,0,9.39823,4.497388,19.639564,0,36.912219,"2::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",2,2,69,175,2,69,0,0,0,0,0,0,13.602857,3.42917,53.959916,0,10.559905,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Clinical improvement as measured by the ACR50 response criteria or by the EULAR good response criteria at 24 weeks stratified for sex",2,2,66,128,8,121,0,0,0,0,0,0,7.798828,3.910212,15.554585,0,42.068338,"2::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Number of patients with serious adverse events at any time stratified for sex",3,1,0,117,2,44,0,0,0,0,0,0,0.076271,0.003734,1.558031,0,5.741161,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Number of patients with serious adverse events at any time stratified for sex",3,1,2,113,3,118,0,0,0,0,0,0,0.696165,0.118521,4.089123,0,16.669604,"3::1","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2009",2009,"Number of patients with serious adverse events at any time stratified for sex",3,2,7,175,5,69,0,0,0,0,0,0,0.552,0.181316,1.68051,0,42.158827,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
"Kavanaugh 2017",2017,"Number of patients with serious adverse events at any time stratified for sex",3,2,5,128,5,121,0,0,0,0,0,0,0.945313,0.280645,3.184145,0,35.430408,"3::2","CD013614_pub2_data",FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,FALSE,TRUE,TRUE,FALSE,FALSE,FALSE,TRUE
